Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 3
Submit an article Journal homepage
19
Views
1
CrossRef citations to date
0
Altmetric
Miscellaneous

Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment

Gianluca Baio University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
,
Luca Degli Esposti University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
,
Ezio Degli Esposti University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
,
Stefania Saragoni University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
,
Alessandro Capone University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
,
Pierluigi Russo University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
&
Fabio Pammolli University of Florence, Department of Statistics G Parenti, Viale Morgagni 53, 50134, Florence, Italy. [email protected]
 show all
Pages 227-236 | Published online: 09 Jan 2014

References

  • MacMahon SW, Cutler JA, Furberg CD etal The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised clinical trials. Ping. Cardiovascular Dis. 29\(Suppl. 1), 99–118 (1986).
  • SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). .1. Am Med. Assoc. 265, 3255–3264 (1991).
  • Hypertension prevalence and the status of awareness, treatment and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 7, 457–468 (1985).
  • Jones JK, Gorkun L, Dan JF et al Discontinuation of and changes in the treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Brit. Merl 1. 311, 293–295 (1995).
  • Mancia G, Sega R, Milesi C et al. Blood pressure control in the hypertensive population. Lancet 349, 454–457 (1997).
  • Avorn J, Monette J, LeLorier J et al. Persistence of use of lipid-lowering medications: a cross-national study. J. Am. Med. Assoc. 279(18), 1458–1462 (1998).
  • LeLorier J, Page V, Castilloux AM et al The management of new symptoms of dyspepsia in Quebec elderly. Can. Gastroenterology11(8), 669–672 (1997).
  • Spitzer WO, Suissa S, Ernst P et al The use of 13-agonists and the risk of death and near death from asthma. N Eng. I Med. 326, 501 —505 (1992).
  • Degli Esposti E, Sturani A, Degli Esposti L eta]. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int. .1. Gun. Pharmacol Therapeutics 6, 251–258 (2001).
  • •One the first ever published about an Italian outcome research study on hypertension and was useful to give a structure to the data collection methodology used also in the present study
  • Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). The sixth report of the JNC VI. Arch. Intern. Med. 157, 2413–2446 (1997).
  • Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 8, 257–261 (1999).
  • •Developed the original bayesian methodology used in our paper and was a crucial contribution to modem health economics literature.
  • Briggs AH. Bayesian cost-effectiveness analysis for frequentists: interpreting cost-effectiveness acceptability curves. (Work In Progress).
  • O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ. (In Press).
  • •Interesting as it gives a number of themetical reasons why one should apply bayesian methodology in clinical studies. Many of the advantages are explained on a very detailed level from the statistical point of view.
  • O'Hagan A, Stevens JW, Montmartin J. Bayesian cost effectiveness analysis from clinical trial data. Stat. Med. 20, 733–753 (2001).
  • Bernardo JM, Smith AFM. Bayesian Theory. John Wiley and Sons, London, UK (1997).
  • Gelman A, Carlin JB, Stern HS, Rubin D. Bayesian Data Analysis. Chapman Hall. NY, USA (1998).
  • O'Hagan A. Bayesian Inference. In: Kendall Advanced Theory of Statistics, 2B. Arnold, London, UK (1994).
  • Lee PM. Bayesian Statistics. Arnold, London, UK (1998).
  • Gamerman D. Markov Chain Monte Carlo. Chapman Hall, NY, USA (1997).
  • Spiegelhalter D, Thomas A, Best N. WinBUGS, version 1.3. MRC Biostatistics Unit, Cambridge, UK (2000).
  • Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. I Comp. Graph. Statistics 7, 434–455 (1998).
  • Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Statistical Science 7, 457–511 (1992).
  • Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clinical Therapeutics 20, 1–11 (1998).
  • Drummond ME, O'Brien BJ, Stoddar GL, Torrance GW. Methods for the Economic Evaluation of Healthcare Programmes. Oxford University Press, London, UK (1997).
  • Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. PharmacoEconomics 7(3), 242–250 (1995).
  • Miller NH, Hill M, Kottke T, Ockene The multilevel compliance challenge: recommendations for a call to action; a statement for healthcare professionals. Circulation 95, 1085–1090 (1997).
  • Mood AM, Graybill FA, Boes DC. Introduction to the Theory of Statistics. McGraw-Hill, NY, USA (1993).
  • Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Hear t 19(Suppl. C), C59—C65 (1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.